Upgrade to SI Premium - Free Trial

INmune Bio (INMB)

1.35 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/5/26)

Latest Headlines

Form 8-K Inmune Bio, Inc. For: Jun 02 June 2, 2026 4:00 PM - SEC Filing INmune Bio reports positive MRI results in Alzheimer's trial June 2, 2026 8:01 AM - StreetInsider INmune Bio reports positive MRI results in Alzheimer's trial June 2, 2026 8:00 AM - StreetInsider INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial June 2, 2026 8:00 AM - Globe NewsWire INmune Bio Reports Statistically Significant Treatment Effect on Advanced White Matter MRI Biomarker in Phase 2 MINDFuL Alzheimer's Trial June 2, 2026 8:00 AM - StreetInsider INmune Bio publishes phase 2 alzheimer's trial results in peer journal May 15, 2026 8:00 AM - StreetInsider INmune Bio publishes Phase 2 Alzheimer's trial results in peer-reviewed journal May 15, 2026 8:00 AM - StreetInsider INmune Bio Publishes Phase 2 MINDFuL Trial Results in NPJ Dementia, Advancing the XPro™ Platform May 15, 2026 8:00 AM - Globe NewsWire Form 8-K Inmune Bio, Inc. For: May 14 May 14, 2026 4:06 PM - SEC Filing INmune Bio receives FDA fast track designation for alzheimer's drug May 14, 2026 8:00 AM - StreetInsider INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease May 14, 2026 8:00 AM - StreetInsider INmune Bio receives FDA fast track designation for alzheimer's drug May 14, 2026 8:00 AM - StreetInsider INmune Bio Receives FDA Fast Track Designation for XPro1595 in Early Alzheimer's Disease May 14, 2026 8:00 AM - Globe NewsWire INmune Bio Named Founding Member of the American Biotech Innovation Alliance (ABIA) as U.S. Biotech Sector Navigates Strategic Inflection Point May 13, 2026 8:00 AM - StreetInsider INmune Bio, Inc. (INMB) Tops Q1 EPS by 7c May 7, 2026 5:13 PM - StreetInsider Form 10-Q Inmune Bio, Inc. For: Mar 31 May 7, 2026 4:20 PM - SEC Filing INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update May 7, 2026 4:00 PM - StreetInsider Form 8-K Inmune Bio, Inc. For: Apr 29 May 5, 2026 4:31 PM - SEC Filing INmune Bio expands CORDStrom platform collaboration with Anthony Nolan May 5, 2026 4:00 PM - StreetInsider INmune Bio and Anthony Nolan Announce Strategic Expansion of CORDStrom™ MSC Platform Collaboration to Target RDEB, Oncology, and Inflammatory Diseases May 5, 2026 4:00 PM - Globe NewsWire Biotech Leaders Launch National Alliance to Define the Future of American Innovation May 5, 2026 7:00 AM - BizWire INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th April 30, 2026 8:00 AM - Globe NewsWire Form DEF 14A Inmune Bio, Inc. For: Jun 16 April 23, 2026 7:12 PM - SEC Filing INmune Bio presents data showing INB03 reduces cancer metastases April 16, 2026 11:42 AM - StreetInsider INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models April 16, 2026 11:42 AM - Globe NewsWire INmune Bio presents preclinical data on INB03 for breast cancer April 16, 2026 8:00 AM - StreetInsider INmune Bio Inc. Announces New Preclinical Data at AACR 2026 Demonstrating INB03 (XPro1595) Overcomes Resistance and Reduces Metastases in HER2-Positive Breast Cancer Models April 16, 2026 8:00 AM - StreetInsider Form 10-K Inmune Bio, Inc. For: Dec 31 March 30, 2026 5:31 PM - SEC Filing INmune Bio reports 2025 financial results, plans regulatory filings March 30, 2026 4:00 PM - StreetInsider INmune Bio Inc. Announces 2025 Results and Provides Business Update March 30, 2026 4:00 PM - StreetInsider INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th. March 24, 2026 8:00 AM - StreetInsider INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease March 19, 2026 8:00 AM - StreetInsider Lucid Capital Markets Upgrades INmune Bio Inc. (INMB) to Buy, 'Factoring in RDEB' March 11, 2026 6:03 AM - StreetInsider Full Article List